Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders. - Sordi V; Monti P; Lampasona V; Melzi R; Pellegrini S; Keymeulen B; Gillard P; Linn T; Bosi E; Rose L; Pozzilli P; Giorgino F; et al. (Frontiers in endocrinology, 2023)